Standard BioTools Inc (NASDAQ: LAB) on Friday, soared 1.10% from the previous trading day, before settling in for the closing price of $1.82. Within the past 52 weeks, LAB’s price has moved between $1.21 and $3.04.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -0.06% annually for the last half of the decade. The company achieved an average annual earnings per share of 62.06%. With a float of $360.22 million, this company’s outstanding shares have now reached $372.26 million.
In an organization with 539 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 48.57%, operating margin of -81.68%, and the pretax margin is -79.83%.
Standard BioTools Inc (LAB) Insider Updates
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Standard BioTools Inc is 3.23%, while institutional ownership is 75.14%. The most recent insider transaction that took place on Nov 12 ’24, was worth 123,098. Before that another transaction happened on Sep 09 ’24, when Company’s Former Officer proposed sale 45,851 for $2.00, making the entire transaction worth $91,725.
Standard BioTools Inc (LAB) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.12 earnings per share (EPS) for the period topping the consensus outlook (set at -0.13) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 62.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.06% during the next five years compared to 8.72% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
Standard BioTools Inc (LAB) is currently performing well based on its current performance indicators. A quick ratio of 3.41 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.44.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.71, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.20 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
Let’s dig in a bit further. During the last 5-days, its volume was 1.56 million. That was inferior than the volume of 2.45 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 90.53%. Additionally, its Average True Range was 0.13.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 52.50%, which indicates a significant increase from 47.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 88.84% in the past 14 days, which was lower than the 103.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8490, while its 200-day Moving Average is $2.1768. However, in the short run, Standard BioTools Inc’s stock first resistance to watch stands at $1.8667. Second resistance stands at $1.8933. The third major resistance level sits at $1.9267. If the price goes on to break the first support level at $1.8067, it is likely to go to the next support level at $1.7733. Assuming the price breaks the second support level, the third support level stands at $1.7467.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
Market capitalization of the company is 692.49 million based on 372,259K outstanding shares. Right now, sales total 106,340 K and income totals -74,660 K. The company made 44,970 K in profit during its latest quarter, and -26,940 K in sales during its previous quarter.
